Cardiff Oncology Inc. (NASDAQ: CRDF)
$2.59
+0.0800 ( +3.19% ) 453.9K
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").
Market Data
Open
$2.59
Previous close
$2.51
Volume
453.9K
Market cap
$116.32M
Day range
$2.53 - $2.65
52 week range
$0.94 - $6.42
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
ars | Annual reports | 1 | Apr 25, 2024 |
def | Proxies and info statements | 15 | Apr 25, 2024 |
8-k | 8K-related | 16 | Apr 08, 2024 |
4 | Insider transactions | 1 | Mar 07, 2024 |
4 | Insider transactions | 1 | Mar 07, 2024 |
4 | Insider transactions | 1 | Mar 07, 2024 |
4 | Insider transactions | 1 | Mar 07, 2024 |
10-k | Annual reports | 77 | Feb 29, 2024 |
8-k | 8K-related | 55 | Feb 29, 2024 |
8-k | 8K-related | 78 | Jan 08, 2024 |